Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known which combination chemotherapy regimen followed by radiation therapy is more effective in treating aggressive non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens followed by radiation therapy to compare how well they work in treating patients with aggressive non-Hodgkin's lymphoma.

Study Overview

• Status: Completed
• Conditions: Lymphoma
• Intervention / Treatment: Drug: cyclophosphamide; Radiation: radiation therapy; Drug: prednisone; Drug: etoposide; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Biological: filgrastim; Drug: EPOCH regimen

Detailed Description

OBJECTIVES:

• Compare the efficacy of standard-dose vs high-dose cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone followed by radiotherapy, in terms of time to treatment failure, in patients with aggressive non-Hodgkin's lymphoma.
• Compare the acute and long-term toxic effects of these regimens in these patients.
• Compare the complete response rate, survival and tumor control, and disease-free survival in patients treated with these regimens.
• Analyze the time to relapse after radiotherapy in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to LDH levels (no greater than upper limit of normal [ULN] vs greater than ULN), initial bulky disease (yes vs no), stage (I or II vs II or IV), ECOG performance status (0 or 1 vs 2 or 3), and participating center. Patients are randomized to 1 of 2 treatment arms as follows:

• Arm I (Standard dose): Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; etoposide IV on days 1-3; and oral prednisone on days 1-5 (CHOEP) in standard doses.
• Arm II (Escalated dose): Patients receive high-dose CHOEP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously on days 6-12.

In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of CHOEP chemotherapy, patients with initial bulky disease or extranodal involvement undergo radiotherapy 5 days a week for 4 weeks.

Patients who undergo radiotherapy are followed at 2 months after radiotherapy. All patients (including those who undergo radiotherapy) are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 389 patients were accrued for this study.

• Study Type: Interventional
• Enrollment (Actual): 392
• Phase: Phase 3

Contacts and Locations

Study Locations

• Germany
  • Aachen, Germany, 52070
    • Haematologisch Onkologische Praxis
  • Amberg, Germany, D-92224
    • Klinikum St. Marien
  • Ansbach, Germany, D-91522
    • Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie
  • Aschaffenburg, Germany, 63739
    • Specialist Practice for Oncology
  • Aschaffenburg, Germany, D-63739
    • II. Medizinische Klinik
  • Augsburg, Germany, D-86156
    • Klinikum Augsburg
  • Augsburg, Germany, 86150
    • Haematologische Praxis
  • Augsburg, Germany, 86150
    • Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg
  • Aurich, Germany, D-26603
    • Kreiskrankenhaus Aurich
  • Bad Hersfeld, Germany, D-36251
    • Kreiskrankenhaus
  • Bad Saarow, Germany, D-15526
    • Humaine - Clinic
  • Bayreuth, Germany, D-95445
    • Krankenhaus Hohe Warte Mediziniche Klinik
  • Berlin, Germany, 13357
    • Onkolog - Haematolog Schwerpunktpraxis
  • Berlin, Germany, D-13125
    • Charité - Campus Charité Mitte
  • Bernburg, Germany, D-06406
    • Hospital Complex Bernburg
  • Bietigheim, Germany, D-74319
    • Krankenhaus Bietigheim
  • Bocholt, Germany, D-46397
    • Saint Agnes Hospital
  • Bochum, Germany, D-44892
    • Knappschaft Krankenhaus
  • Bochum, Germany, D-44791
    • Saint Josef Hospital
  • Bonn, Germany, D-53111
    • Medizinische Poliklinik
  • Bonn, Germany, D-53113
    • Rheinische Friedrich-Wilhelms-Universitat
  • Bremen, Germany, D-28239
    • DIAKO Ev. Diakonie Krankenhaus gGmbH
  • Bunde, Germany, D-32257
    • Medizinische Klinik Am Lukas - Krankenhaus
  • Celle, Germany, D-29223
    • General Hospital
  • Chemnitz, Germany, D-09113
    • Hospital Kuchwald Chemnitz
  • Cologne-Kalk, Germany, D-51105
  • Cottbus, Germany, D-03048
    • Carl - Thiem - Klinkum Cottbus
  • Darmstadt, Germany, D-64283
    • Klinikum Darmstadt
  • Dortmund, Germany, D-44137
    • Saint Johannes Hospital Dortmund
  • Dresden, Germany, D-01307
    • Universitätsklinikum Carl Gustav Carus
  • Duesseldorf, Germany, D-40489
    • Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth
  • Duisburg, Germany, D-47166
    • St. Johannes Hospital - Medical Klinik II
  • Dulmen, Germany, D-48249
    • Franz Hospital Dulmen
  • Emden, Germany, D-26721
    • Hans - Susemihl - Krankenhaus
  • Erfurt, Germany, 99089
    • Klinikum Erfurt
  • Eschweiler, Germany, 52249
    • St. Antonius Hospital
  • Essen, Germany, D-45147
    • Universitaetsklinikum Essen
  • Essen, Germany, D-45239
    • Evangelisches Krankenhaus Essen-Werden
  • Frankfurt, Germany, 60488
    • Krankenhaus Nordwest
  • Frankfurt/Oder, Germany, 15236
    • Klinikum Frankfurt (Oder) GmbH
  • Freiburg, Germany, D-79110
    • Evang. Deaconess Hospital Freiburg
  • Fulda, Germany, 36043
    • Municipal Hospital Complex
  • Gehrden, Germany, 30989
    • Robert - Koch Hospital
  • Gießen, Germany, D-35392
    • Centre for Internal Medicine Gießen
  • Greifswald, Germany, D-17489
    • Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet
  • Gutersloh, Germany, 33332
    • Staedtisches Klinikum Guetersloh
  • Göttingen, Germany, D-37075
    • Universitaetsklinikum Göttingen
  • Hagen, Germany, D-58095
    • Allgemeines Krankenhaus Hagen
  • Hagen, Germany, 58095
    • St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH
  • Halle, Germany, 06120
    • Krankenhaus Martha-Maria Halle-Doelau gGmbH
  • Halle, Germany, D-06097
    • Universitaetsklinikum Halle
  • Halle/Saale, Germany, 06110
    • Krankenhaus St. Elisabeth und St. Barbara
  • Hamburg, Germany, 20095
  • Hamburg, Germany, D-22767
    • Haematologisch-Onkologische Praxis Altona
  • Hamburg, Germany, D-20251
    • Universitaetsklinikum Hamburg-Eppendorf
  • Hamburg, Germany, D-22413
    • Asklepios Klinik Nord Heidberg
  • Hamburg, Germany, D-22763
    • Allgemeines Krankenhaus Altona
  • Hamm, Germany, D-59063
    • Evangelische Krankenhaus Hamm
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover
  • Hannover, Germany, 30159
  • Hannover, Germany, 30559
    • Henriettenstiftung Krankenhaus
  • Hannover, Germany, 30449
    • Krankenhaus Siloah - Medizinische Klinik II
  • Harrislee, Germany, D-24955
    • Oncology Specialists Clinic
  • Heidelberg, Germany, 69115
    • Medizinische Universitaetsklinik und Poliklinik
  • Heidelberg, Germany, D-69126
    • Thoraxklinik Heidelberg
  • Heidenheim, Germany, 89522
    • Regional Hospital Heidenheim
  • Heilbronn, Germany, D-74172
    • Regional Hospital Am Plattenwald - Bad Friedrichhall
  • Herford, Germany, 32049
    • Klinikum Herford
  • Herne, Germany, 44625
    • Marienhospital at Ruhr University Bochum
  • Herrsching Am Ammersee, Germany, D-82211
    • Privatklinik Dr. R. Schindlbeck GmbH & Co. KG
  • Hildesheim, Germany, 31134
    • Onkologische Schwerpunktpraxis
  • Holzminden, Germany, D-37603
    • Evang. Hospital
  • Homburg, Germany, D-66424
    • Universitaetsklinikum des Saarlandes
  • Homburg, Germany, 66421
    • Medical University Hospital Homburg
  • Hoyerswerda, Germany, D-02977
    • Hospital Complex Hoyerswerda
  • Jena, Germany, D-07743
    • Gemeinschaftspraxis Innere Medizin
  • Jena, Germany, D-07747
    • Klinikum der Friedrich-Schiller Universitaet Jena
  • Kaiserslautern, Germany, D-67655
    • Municipal Hospital Complex of the University
  • Karlsruhe, Germany, D-76133
    • Staedtisches Klinikum Karlsruhe gGmbH
  • Kassel, Germany, D-34121
    • Red Cross Hospital Kassel
  • Kiel, Germany, D-23116
    • Staedtisches Krankenhaus Kiel
  • Koblenz, Germany, D-56068
    • Praxis fuer Haematologie und Onkologie
  • Koblenz, Germany, D-56068
    • Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH
  • Koln, Germany, D-50924
    • Medizinische Universitaetsklinik I at the University of Cologne
  • Koln, Germany, D-50677
    • Praxis Fuer Haematologie Internistische Onkologie
  • Koln-Merheim, Germany, D-51109
    • Kliniken der Stadt Koeln gGmbH - Krankenhaus Merheim
  • Kornwestheim, Germany, D-70806
    • Leonardis Clinic
  • Krefeld, Germany, D-47805
    • Klinikum Krefeld GmbH
  • Kronach, Germany, D-96317
    • Frankenwald Klinik
  • Lebach, Germany, D-66822
    • Caritas - Krakenhaus Lebach
  • Leipzig, Germany, D-04103
    • University Leipzig Clinic of Internal Medicine
  • Leipzig, Germany, D-04103
  • Leipzig, Germany, D-04103
    • Medizinische Klinik und Poliklinik III - Universitaetsklinikum Leipzig
  • Leipzig, Germany, D-04129
    • Staedtisches Klinikum "St. Georg" Leipzig
  • Lemgo, Germany, D-32657
    • Klinikum Lippe - Lemgo
  • Limburg, Germany, D-65549
    • St. Vincenz Hospital Limburg
  • Lingen, Germany, D-49808
    • St. Bonifatius Hospital Lingen
  • Lippstadt, Germany, D-59555
    • Dreifaltigkeits Hospital
  • Ludwigsburg, Germany, D-71460
    • Klinikum Ludwigsburg
  • Ludwigshafen, Germany, D-67067
    • St. Marien Hospital Ludwighafen
  • Ludwigshafen, Germany, D-67063
    • Klinikum der Stadt Ludwigshafen am Rhein
  • Luebeck, Germany, D-23538
    • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
  • Magdeburg, Germany, D-39120
    • Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg
  • Magdeburg, Germany, D-39104
    • Staedtisches Klinikum Magdeburg - Altstadt
  • Mainz, Germany, D-55131
    • Johannes Gutenberg University
  • Manheim, Germany, D-68305
    • German CML Study Group
  • Marburg, Germany, D-35037
  • Marburg, Germany, D-35043
    • Philipps-Universitaet Marburg Klinikum
  • Mayen, Germany, D-56727
    • Regional Hospital Mayen
  • Minden, Germany, D-32423
    • Klinikum Minden
  • Minden, Germany, D-32427
  • Monchenglabach, Germany, D-41061
    • Ev. Hospital Bethesda
  • Monchengladbach, Germany, D-41063
    • Hospital Maria-Hilf II
  • Monchenglasbach/Rheydt, Germany, D-41239
  • Mulheim/Ruhr, Germany, D-45468
    • St. Marien Hospital - Muelheim an der Ruhr
  • Munchberg, Germany, D-95213
    • Kreiskrankenhaus Muenchberg
  • Munchen, Germany, D-80335
    • Munich Oncologic Practice at Elisenhof
  • Munchen, Germany, D-80336
    • Klinikum der Universitaet Muenchen - Innenstadt Campus
  • Munich, Germany, D-81377
    • Klinikum der Universitaet Muenchen - Grosshadern Campus
  • Munich, Germany, D-80804
    • Krankenhaus Muenchen Schwabing
  • Munster, Germany, D-48129
    • Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster
  • Mülheim, Germany, D-45466
    • Evangelisches Krankenhaus - Mülheim
  • Neumarkt, Germany, D-92318
    • Regional Hospital Neumarkt
  • Neunkirchen, Germany, D-66538
    • Staedtisches Klinikum Neunkirchen gGmbH
  • Neuss, Germany, D-41464
    • Lukaskrankenhaus Neuss
  • Nurnberg, Germany, D-90340
    • Klinikum Nuernberg - Klinikum Nord
  • Offenburg, Germany, D-77654
    • Klinikum Offenburg
  • Oldenburg, Germany, D-26133
    • Klinikum Oldenburg
  • Oldenburg, Germany, D-26122
    • Ev. Hospital Oldenburg
  • Oldenburg, Germany, D-26121
    • Hematologische Praxis
  • Osnabrück, Germany, D-49076
    • Paracelsus - Klinik Osnabrück
  • Pforzheim, Germany, D-49 7231 9690
    • Municipal Hospital Complex
  • Potsdam, Germany, D-14467
    • Klinikum Ernst von Bergmann
  • Radebeul, Germany, D-01445
    • Kreiskrankenhaus Radebeul
  • Ravensburg, Germany, D-88212
    • Krankenhaus St. Elisabeth - Ravensburg
  • Regensburg, Germany, D-93049
    • Krankenhaus Barmherzige Brueder Regensburg
  • Regensburg, Germany, D-93042
    • Klinikum der Universitaet Regensburg
  • Regensburg, Germany, D-93047
    • Hematologische Onkologische Praxis
  • Rheine, Germany, D-48431
    • Jakobi Krankenhaus
  • Rostock, Germany, D-18057
    • Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock
  • Rostock, Germany, D-18257
  • Rostock, Germany, D-18057
    • Klinik und Poliklinik fuer Strahlentherapie - Universitaetsklinikum Rostock
  • Saarbrucken, Germany, D-66113
    • Caritasklinik St. Theresia
  • Saarbrucken, Germany, D-66113
    • Schwerpunktpraxis fuer Haematologie und Onkologie
  • Saarlouis, Germany, D-66713
    • St. Elizabeth-Klinik Saarlouis
  • Schleswig, Germany, D-24837
    • Martin - Luther Hospital
  • Schwabisch Hall, Germany, D-74523
    • Deaconess Hospital
  • Schweinfurt, Germany, D-97422
    • Leopoldina - Krankenhaus
  • Siegen, Germany, D-57074
    • Evang. Jung-Stilling Hospital
  • Solingen, Germany, D-42697
    • St. Lukas - Clinic Solingen
  • Stuttgart, Germany, D-70174
    • Klinik fuer Onkologie - Katharinenhospital Stuttgart
  • Stuttgart, Germany, D-70176
    • Diakonie Klinikum Stuttgart
  • Stuttgart, Germany, D-70191
    • Klinikum Stuttgart - Buergerhospital
  • Stuttgart, Germany, D-70376
    • Robert-Bosch-Krankenhaus
  • Stuttgart, Germany, D-70374
    • Hospital Bad Cannstatt
  • Thuine, Germany, D-49832
    • St. Elisabeth Hospital Thuine
  • Traunstein, Germany, D-83278
    • Regional Hospital Traunstein
  • Trier, Germany, D-54290
    • Krankenanstalt Mutterhaus der Borromaerinnen
  • Trier, Germany, D-54292
    • Krankenhaus Der Barmherzigen Brueder
  • Trier, Germany, D-54290
  • Tutzing, Germany, D-82327
    • Hospital Tutzing
  • Ulm, Germany, D-89081
    • Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm
  • Unna, Germany, D-59403
    • Ev. Hospital Unna
  • Vechta, Germany, D-49377
    • St. Marienhospital - Vechta
  • Villingen-Schwenningen, Germany, D-78045
    • Klinikum Der Stadt Villingen - Schwenningen
  • Waldbrol, Germany, D-51545
    • Regional Hospital Waldbrol
  • Wetzlar, Germany, D-35578
    • Hospital Wetzler
  • Wiesbaden, Germany, D-65199
    • Dr. Horst-Schmidt-Kliniken
  • Wiesbaden, Germany, D-65191
    • Deutsche Klinik fuer Diagnostik
  • Witten, Germany, D-58455
    • Ev. Hospital Witten-Herdecke
  • Wuerzburg, Germany, D-97070
    • University Würzburg
  • Wuppertal, Germany, D-42283
    • Kliniken St. Antonius
  • Zwickau, Germany, D-08060
    • Municipal Hospital Complex Zwickau
• Switzerland
  • Zurich, Switzerland, CH-8091
    • Universitaetsspital Zuerich
  • Zurich, Switzerland, D-8063
    • City Hospital Triemli

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Histologically confirmed aggressive non-Hodgkin's lymphoma

  • Previously untreated disease

• Favorable prognosis

  • International Prognostic Index score of 0-1
• No more than 25% marrow involvement

PATIENT CHARACTERISTICS:

Age

• 18 to 60

Performance status

• ECOG 0-3 OR
• Karnofsky 40-100%

Life expectancy

• Not specified

Hematopoietic

• Platelet count at least 100,000/mm^3
• WBC at least 2,500/mm^3

Hepatic

• No active hepatitis infection

Renal

• Not specified

Other

• HIV negative
• Not pregnant or nursing
• No relevant accompanying disease
• No other concurrent malignancy
• No contraindications to any study medications
• No prior noncompliance by patient

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• No prior radiotherapy

Surgery

• Not specified

Other

• No other concurrent participation in another treatment study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: CHOEP-21; CHOEP-21-Schema: Cyclophosphamid (750 mg/m2 i.v. d1), Doxorubicin (50 mg/m2 i.v. d1), Vincristin (2 mg i.v. d1), Etoposid (100 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)	Drug: cyclophosphamide; Radiation: radiation therapy; Drug: prednisone; Drug: etoposide; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Biological: filgrastim; Drug: EPOCH regimen
Experimental: high CHOEP-21; High-CHOEP-21-Schema: Cyclophosphamid (1400 mg/m2 i.v. d1), Doxorubicin (32,5 mg/m2 i.v. d1+2), Vincristin (2 mg i.v. d1), Etoposid (175 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)	Drug: cyclophosphamide; Radiation: radiation therapy; Drug: prednisone; Drug: etoposide; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Biological: filgrastim; Drug: EPOCH regimen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to treatment failure (TTF) at first relapse	Time to Treatment failure using the Kaplan_Meier-Method	3 years within study and periodically after study completion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete response rate at first relapse	Number of complete remission (CR) and unconfirmed complete Remission (CRu)	3 years within study and periodically after study completion
Survival time	Time till death (whatever cause)	3 years within study and periodically after study completion
Tumor control	Calcution of treatment Duration using the Kaplan-Meier method	thought the treatment
Disease-free survival	Time of disease-free survivial	3 years within study and periodically after study completion

Collaborators and Investigators

• Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group

Publications and helpful links

General Publications

• Trumper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol. 2008 Mar;19(3):538-44. doi: 10.1093/annonc/mdm497. Epub 2008 Jan 22.
• Pfreundschuh M, Zwick C, Zeynalova S, Duhrsen U, Pfluger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trumper L, Rube C, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2008 Mar;19(3):545-52. doi: 10.1093/annonc/mdm514. Epub 2007 Dec 6.

Study record dates

Study Major Dates

• Study Start: April 1, 2002
• Primary Completion (Actual): December 5, 2006
• Study Completion (Actual): December 5, 2006

Study Registration Dates

• First Submitted: February 5, 2003
• First Submitted That Met QC Criteria: February 5, 2003
• First Posted (Estimate): February 6, 2003

Study Record Updates

• Last Update Posted (Actual): May 18, 2021
• Last Update Submitted That Met QC Criteria: May 14, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: stage III adult diffuse large cell lymphoma; stage III adult immunoblastic large cell lymphoma; stage III adult Burkitt lymphoma; stage IV grade 3 follicular lymphoma; stage IV adult diffuse large cell lymphoma; stage IV adult immunoblastic large cell lymphoma; stage IV adult Burkitt lymphoma; stage III grade 3 follicular lymphoma; stage III adult diffuse mixed cell lymphoma; stage IV adult diffuse mixed cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma; stage III adult lymphoblastic lymphoma; stage IV adult lymphoblastic lymphoma; contiguous stage II mantle cell lymphoma; noncontiguous stage II mantle cell lymphoma; noncontiguous stage II adult diffuse large cell lymphoma; noncontiguous stage II adult diffuse mixed cell lymphoma; noncontiguous stage II adult lymphoblastic lymphoma; noncontiguous stage II grade 3 follicular lymphoma; noncontiguous stage II adult Burkitt lymphoma; noncontiguous stage II adult immunoblastic large cell lymphoma; stage I mantle cell lymphoma; stage I adult Burkitt lymphoma; contiguous stage II adult Burkitt lymphoma; contiguous stage II adult immunoblastic large cell lymphoma; stage I adult immunoblastic large cell lymphoma; contiguous stage II grade 3 follicular lymphoma; stage I grade 3 follicular lymphoma; contiguous stage II adult diffuse large cell lymphoma; contiguous stage II adult diffuse mixed cell lymphoma; stage I adult diffuse large cell lymphoma; stage I adult diffuse mixed cell lymphoma; contiguous stage II adult lymphoblastic lymphoma; stage I adult lymphoblastic lymphoma
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Cyclophosphamide; Etoposide; Prednisone; Doxorubicin; Liposomal doxorubicin; Vincristine
• Other Study ID Numbers: CDR0000269371; DSHNHL-1999-2; EU-20242